
Kinetiq Inc (AKA: Kinetiq Therapeutic) Profile last edited on: 5/16/2018
CAGE: 7L4G2
UEI: GDK8FEJKMLL7
Business Identifier: Next Generation Enzyme Therapeutics Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 32
County: Los Angeles
Congr. District: 32
County: Los Angeles
Public Profile
Kinetiq is organized around developing the next generation of enzyme-based treatments for various diseases. Asociated innovations include improving both the upstream molecules and the downstream manufacturing process. Principals of the firm are developing a novel chromatography purification device that is capable of purifying commercial quantities of biological drugs in an easy-to-use and cost-effective way. This "plug-and-play" concept device also utilizes a unique simulation software which takes advantage of computational power in order to make process development much simpler and more effective than the traditional approach. The effort is to decrease the "burden of treatment" on patients - financially, physically, and mentally - especially critical for enzyme-based therapies because patients would normally need to follow such treatments for a lifetime.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
1-4Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2018 | 1 | NIH | $311,668 | |
Project Title: Subcutaneous Replacement Enzymes for Fabry Disease | ||||
0 | 1 | NIH | $306,870 | |
Project Title: Evaluating a Novel Enzymatic Modality for the Treatment of Fanconi Anemia |
Key People / Management
Mingju Cao
Yue Liao
Yue Liao
Company News
There are no news available.